Antibe Therapeutics Inc (ATBPF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 03-2018 | 03-2017 | 03-2016 | 03-2015 | 03-2014 | |
| Sales | 6,640 | 6,898 | 3,390 | 0 | 0 |
| Cost of Goods | 4,006 | 3,901 | 1,819 | N/A | N/A |
| Gross Profit | 2,633 | 2,997 | 1,571 | N/A | N/A |
| Operating Expenses | 7,839 | 7,866 | 5,061 | 3,896 | 2,553 |
| Operating Income | -5,199 | -3,968 | -2,671 | -3,896 | -2,553 |
| Interest Expense | 825 | 690 | 248 | 0 | 14 |
| Other Income | 14 | 3 | 248 | 18 | 20 |
| Pre-tax Income | -6,011 | -4,655 | -2,671 | -3,878 | -2,547 |
| Income Tax | -214 | -278 | -661 | N/A | N/A |
| Net Income Continuous | -5,797 | -4,377 | -2,010 | -3,878 | -2,547 |
| Net Income | $-5,797 | $-4,377 | $-2,010 | $-3,878 | $-2,547 |
| EPS Basic Total Ops | -0.39 | -0.46 | -0.31 | -1.06 | -0.95 |
| EPS Basic Continuous Ops | -0.38 | -0.46 | -0.32 | -1.05 | -0.97 |
| EPS Diluted Total Ops | -0.39 | -0.46 | -0.31 | -1.06 | -0.95 |
| EPS Diluted Continuous Ops | -0.38 | -0.46 | -0.32 | -1.05 | -0.97 |
| EPS Diluted Before Non-Recurring Items | -0.40 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $-4,905 | $-3,694 | $-2,300 | $-3,896 | $-2,538 |